Search

Introduction: Stratification of risk for major complications (including mortality) is the current fundamental clinical strategy for making therapeutic decisions in patients with pulmonary arterial hypertension. However, it is noticeable that most of patients are grouped in the intermediate category both at the time of diagnosis and during follow-up. Highlighting the relevance and necessity to improve discrimination and therapeutic options for patients at intermediate risk. Objective: To define a series of recommendations on the proper subclassification, follow-up, and treatment of adult patients with pulmonary arterial hypertension at intermediate risk, adapted to the Colombian context. Method: 15 experts in pulmonary hypertension were invited. They voted according to the modified Delphi methodology around 14 questions, on which a systematic review of the literature was carried out in several bibliographic bases: VHL, Cochrane Library, PubMed, Medline and Web of Science. The MeSh and DeCs criteria for each question were used without language or time limits. Results and discussion: The present study provides a series of 18 consensus recommendations on stratification, treatment and other sections. Additionally, the initiative makes it possible to identify the insufficiency of scientific studies in our country that determine the behavior of the disease, access barriers and availability of medicines in our country. [ABSTRACT FROM AUTHOR]

Introduction: Acute lymphoblastic leukemia is the most common pediatric cancer. (40%) of all cancer pathology. Survival has increased is estimated that about 80-85% achieve a cure. Prognostic factors orient the treatment protocol adapted to the risk of each individual. The intermediate risk, it is often difficult to classify .It aims to increase survival intensifying treatment and reducing toxic effects. The objective is to evaluate the survival of patients with acute lymphoblastic leukemia who were treated with intermediate-risk protocol, survival around 70% is estimated.. Material and Methods: a cross-sectional study with data obtained from clinical records of oncology at Children's Hospital of the State of Sonora, clinical records 4 years of follow up with a diagnosis of acute lymphoblastic leukemia intermediate risk with treatment of 30 months of continuous complete remission. Statistical analysis was performed with descriptive measurements, chi2 and survival curves Kapplan Meier. Results: Free survival by Kaplan Meier mediated disease 3.5 years is 50%. 10 relapsed (50%) of these 35% were early and 15% late. Patients without relapse 70% currently has more than 24 months in surveillance. The most common site of relapse is bone marrow 30% Discussion: Survival is below that reported in the international literature. One factor is the difficulty in classifying the intermediate risk according to not well standardized clinical criteria. The percentage of relapse to bone marrow failure alert to systemic disease control. It is well established that the levels of minimal residual disease during induction is an important pronostic factors. Conclusion: It is necessary to expand the cabinet studies with which we in our hospital to define intermediate risk criteria and thus have an impact on survival. It requires definitely intensify the treatment of this patient group. [ABSTRACT FROM AUTHOR]